Drug Approval | November 24, 2023
Lupin receives tentative approval from USFDA for Canagliflozin Tablets
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
This product will be manufactured at Lupin’s Pithampur facility in India
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Subscribe To Our Newsletter & Stay Updated
